EBEman A. M. Beshr

Eman A. M. Beshr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eman A. M. Beshr has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Heba A. Hassan

    Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt

    3 shared publications
  • Hend A. A. Ezelarab

    Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt

    3 shared publications
  • Samar Hafez Abbas

    Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt

    3 shared publications
  • Ahmed M. Sayed

    Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, 62513 Beni-Suef, Egypt

    2 shared publications
  • Taha F. S. Ali

    Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt

    2 shared publications
  • Adel A. Marzouk

    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt; National Center for Natural Products Research, School of Pharmacy, University of Mississippi, MS 38677, USA

    1 shared publication

Latest Publications

  • Open Access

    Antimicrobial activity and antifungal mechanistic study of 3‑substituted oxindoles against Aspergillus niger

    by Hend A. A. Ezelarab, Maisra M. El-Bouseary, Ramadan Yahia, Rehab Mahmoud Abd El-Baky, Mohamed A. Mawhoup, Eman Farouk Ahmed, Ghada M. Sadiq, Taha F. S. Ali, Samar H. Abbas, Heba A. Hassan, et al.

    A series of 3-substituted oxindole derivatives 3a-j was synthesized. The target compounds 3a-j were investigated for their potential antibacterial and antifungal activities. S. aureus, MRSA, E. faecalis, P. aeruginosa, K. pneumonia, and E. coli were used for testing the antibacterial activity, while Candida albicans and Aspergillus spp, were used for antifungal activity of the tested compounds. Compounds 3i and 3j exhibited the strongest activity, particularly against Gram-positive bacteria. Antifungal activity was tested against Aspergillus spp . and Candida albicans using the agar diffusion method, with a final concentration of 10,000 µg/mL per well. Eight compounds inhibited Aspergillus spp., while only compound 3g was active against C. albicans . Compound 3f displayed the highest antifungal activity (inhibition zone = 20 mm) compared with itraconazole with a final concentration of 100 µg/mL per well (30 mm). Minimum inhibitory concentration (MIC) testing confirmed compound 3f as the most potent antifungal, with an MIC of 7.5 µg/mL against Aspergillus niger , lower than that of clotrimazole (12.5 µg/mL). Further investigations showed that compound 3f exerted its effect by disrupting fungal cell wall integrity without binding ergosterol. Docking studies of compound 3f in the active sites of chitin deacetylase AngCDA (PDB ID: 7BLY) and the 1,3-β-glucan synthase (8JZN) enzymes proved its dual-target mechanism ability to inhibit the cell wall biosynthesis. These findings highlight compound 3f as a promising lead scaffold for the development of new antifungal agents targeting fungal cell wall biosynthesis.


  • Novel chalcone candidates as potential in vitro and in vivo anti-inflammatory agents: Synthesis, in silico docking, multitarget bioevaluation and molecular dynamic simulation

    by Alshimaa Kh.M. Ahmed, Eman A.M. Beshr, Ibrahim M. Salem, Osama A.A. Ahmed, Tarek S. Ibrahim, Deiaa E. Elsayed Abouzed, Ahmed Mostafa Mahmoud, Mamdouh F.A. Mohamed


  • Open Access

    Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia

    by Hend A. A. Ezelarab, Taha F. S. Ali, Samar H. Abbas, Heba A. Hassan, Eman A. M. Beshr

    Fms-like tyrosine kinase 3 (FLT3) mutation mechanisms are among the most common genetic abnormalities detected in about 30% of acute myeloid leukemia (AML) patients. These mutations are accompanied by poor clinical response, although all these progressions in identifying and interpreting biological AML bio-targets. Several small structured FLT3 inhibitors have been ameliorated to struggle against AML. Despite all these developments regarding these inhibitors, the Overall survival rate is about five years or more in less than one-third of diagnosed AML patients. Midostaurin was the first FDA-approved FLT3 inhibitor in 2017 in the United States and Europe for AML remedy. Next, Gilteritinib was an FDA-approved FLT3 inhibitor in 2018 and in the next year, Quizartinib was approved an as FLT3 inhibitor in Japan. Interestingly, indole-based motifs had risen as advantaged scaffolds with unusual multiple kinase inhibitory activity. This review summarises indole-based FLT3 inhibitors and related scaffolds, including FDA-approved drugs, clinical candidates, and other bioactive compounds. Furthermore, their chemotypes, mechanism of action, and interaction mode over both wild and mutated FLT3 target proteins had been judgmentally discussed. Therefore, this review could offer inspiring future perspectives into the finding of new FLT3-related AML therapies.


  • Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin/EGFR kinase inhibition

    by Mohammed M. Amin, Gamal El-Din A. Abuo-Rahma, Montaser Sh. A. Shaykoon, Adel A. Marzouk, Mohammed A.S. Abourehab, Roshdy E. Saraya, Mohamed Badr, Ahmed M. Sayed, Eman A.M. Beshr


  • Open Access

    New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization

    by Hend A. A. Ezelarab, Taha F. S. Ali, Samar H. Abbas, Ahmed M. Sayed, Eman A. M. Beshr, Heba A. Hassan

    New 3-substituted oxindole derivatives were designed and synthesized as antiproliferative agents. The antiproliferative activity of compounds 6a–j was evaluated against 60 NCI cell lines. Among these tested compounds, compounds 6f and 6g showed remarkable antiproliferative activity, specifically against leukemia and breast cancer cell lines. Compound 6f was the most promising antiproliferative agent against MCF-7 (human breast cancer) with an IC50 value of 14.77 µM compared to 5-fluorouracil (5FU) (IC50 = 2.02 µM). Notably, compound 6f hampered receptor tyrosine EGFR fundamentally with an IC50 value of 1.38 µM, compared to the reference sunitinib with an IC50 value of 0.08 µM. Moreover, compound 6f afforded anti-tubulin polymerization activity with an IC50 value of 7.99 µM as an outstanding observable activity compared with the reference combretastatin A4 with an IC50 value of 2.64 µM. In silico molecular-docking results of compound 6f in the ATP-binding site of EGFR agreed with the in vitro results. Besides, the investigation of the physicochemical properties of compound 6f via the egg-boiled method clarified good lipophilicity, GIT absorption, and blood–brain barrier penetration properties.


  • Open Access

    Pyrrolizine/Indolizine-NSAID Hybrids: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies

    by Mohammed A. S. Abourehab, Alaa M. Alqahtani, Faisal A. Almalki, Dana M. Zaher, Ashraf N. Abdalla, Ahmed M. Gouda, Eman A. M. Beshr

    In the current study, eight new hybrids of the NSAIDs, ibuprofen and ketoprofen with five pyrrolizine/indolizine derivatives were designed and synthesized. The chemical structures of these hybrids were confirmed by spectral and elemental analyses. The antiproliferative activities of these hybrids (5 μM) was investigated against MCF-7, A549, and HT-29 cancer cell lines using the cell viability assay, MTT assay. The results revealed 4–71% inhibition of the growth of the three cancer cell lines, where 8a,e,f were the most active. In addition, an investigation of the antiproliferative activity of 8a,e,f against MCF-7 cells revealed IC50 values of 7.61, 1.07, and 3.16 μM, respectively. Cell cycle analysis of MCF-7 cells treated with the three hybrids at 5 μM revealed a pro-apoptotic increase in cells at preG1 and cell cycle arrest at the G1 and S phases. In addition, the three hybrids induced early apoptotic events in MCF-7 cells. The results of the molecular docking of the three hybrids into COX-1/2 revealed higher binding free energies than their parent compounds 5a,c and the co-crystallized ligands, ibuprofen and SC-558. The results also indicated higher binding free energies toward COX-2 over COX-1. Moreover, analysis of the binding modes of 8a,e,f into COX-2 revealed partial superposition with the co-crystallized ligand, SC-558 with the formation of essential hydrogen bonds, electrostatic, or hydrophobic interactions with the key amino acid His90 and Arg513. The new hybrids also showed drug-likeness scores in the range of 1.06–2.03 compared to ibuprofen (0.65) and ketoprofen (0.57). These results above indicated that compounds 8a,e,f deserve additional investigation as potential anticancer candidates.